These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26943788)

  • 1. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
    Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
    J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
    Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
    PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
    Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
    Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
    Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
    Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
    Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
    Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
    Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
    Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
    Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
    Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
    Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK
    Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.